Bernhardt G. Zeiher - 10 Jun 2026 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: Director
Issuer ticker: TRDA
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:52:10 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jared Cohen, as Attorney-in-Fact

Key filing fact

Bernhardt G. Zeiher filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 12 Jun 2026.

Key facts

This page summarizes Bernhardt G. Zeiher's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 16:52.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001971421 Primary reporting owner

Zeiher Bernhardt G

Relationship: Director
Address: C/O ENTRADA THERAPEUTICS, INC., ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRDA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +19,000
Change %
Price: $0.000000^*
Shares after: 19,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,000
Exercise price: $5.97
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.